RA Capital Nexus Fund II, L.P.'s Net Worth

-$136 Million

Who is RA Capital Nexus Fund II, L.P.?

RA Capital Nexus Fund II, L.P. does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include AN2 Therapeutics, Inc., Cytek Biosciences, Inc., DICE Therapeutics, Inc., Icosavax, Inc., Eliem Therapeutics, Inc., Acumen Pharmaceuticals, Inc., ARS Pharmaceuticals, Inc., Janux Therapeutics, Inc., PepGen Inc., and Acrivon Therapeutics, Inc..

SEC CIK

RA Capital Nexus Fund II, L.P.'s CIK is 0001825376

Past Insider Trading and Trends

2022 was RA Capital Nexus Fund II, L.P.'s most active year for acquiring shares with 51 total transactions. RA Capital Nexus Fund II, L.P.'s most active month to acquire stocks was the month of February. 2021 was RA Capital Nexus Fund II, L.P.'s most active year for disposing of shares, totalling 20 transactions. RA Capital Nexus Fund II, L.P.'s most active month to dispose stocks was the month of July. 2022 saw RA Capital Nexus Fund II, L.P. paying a total of $217,660,840.74 for 25,454,872 shares, this is the most they've acquired in one year. In 2021 RA Capital Nexus Fund II, L.P. cashed out on 38,164,601 shares for a total of $0.00, their largest year based on trade value.